Q-switched 532 nm Nd:YAG laser-assisted depigmentation in vitiligo: a long term follow-up
Keywords:
Nd:YAG, Pigmentary disorder, Skin cancer, Vitiligo, HyperpigmentationAbstract
Background : Vitiligo is an acquired depigmenting disorder. Therapy option include repigmentation of affected skin or depigmentation of unaffected skin. One of the preferred option for widespread and recalcitrant cases is depigmentation therapy with Q-switched pigment laser. Objectives : To evaluate the efficacy and long term safety of Q-switched 532 nm Nd:YAG laser for treatment of extensive and recalcitrant vitiligo. Materials and Methods: Six vitiligo patients with extensive disease and resistance to conventional treatment were enrolled in this study. Treatment with Q-switched 532 nm Nd:YAG laser was performed in all subjects on the exposed and unaffected normal skin. One laser treatment session per area was given with 2-3 month treatment intervals. Results: All patients were on consistent follow-up for 2 to 10 years. The majority were treated with only one laser treatment, with the exception of some areas on the face. One patient who had Koebner phenomenon achieved the best result. No skin malignancy was found in treated skin. Conclusion: Q-switched Nd:YAG 532 nm laser-assisted depigmentation is an effective and safe to eliminate remnants of normal pigmented skin in generalized vitiligo.
References
2. Linthorst Homan MW, Spuls PI, de Korte J, Bos JD, Sprangers MD, van der Veen Jp. The burden of vitiligo: patient characteristics associated with quality of life. J Am Acad Dermatol. 2009; 61: 411–20.
3. Gupta D, Kumari R, Thappa DM. Depigmentation therapies in vitiligo. Indian J Dermatol Venereol Leprol. 2012; 78: 49-58.
4. Mosher DB, Parrish JA, Fitzpatrick TB. Monobenzylether of hydroquinone: A retrospective study of treatment of 18 vitiligo patients and a review of the literature. Br J Dermatol. 1977;97:669-79.
5. Bolognia JL, Lapia BK, Somma S. Depigmentation therapy. Dermatologic Therapy. 2001;14:29-34.
6. Zanini M. Depigmentation therapy for generalized vitiligo with topical 88% phenol solution. An Bras Dermatol. 2005;80:415-6.
7. Di Nuzzo S, Masotti A. Depigmentation therapy in vitiligo universalis with cryotherapy and 4- hydroxyanisole. Clin Exp Dermatol. 2010; 35: 215- 6.
8. Komen L, Zwertbroek L, Burger SJ, van der Veen JP, de Rie MA, Wolkerstorfer A. Q-switched laser depigmentation in vitiligo, most effective in active disease. Br J Dermatol. 2013; 169: 1246-51.
9. Majid I, Imran S. Depigmentation therapy with QSwitched Nd: YAG laser in universal vitiligo. J Cutan Aesthet Surg. 2013; 6: 93-6.
10. Rao J, Fitzpatrick RE. Use of the Q-switched 755- nm alexandrite laser to treat recalcitrant pigment after depigmentation therapy for vitiligo. Dermatol Surg. 2004; 30: 1043-5.
11. Thissen M, Westerhof W. Laser treatment for further depigmentation in vitiligo. Int J Dermatol. 1997;36:386–8.
12. Njoo MD, Vodegel RM, Westerhof W. Depigmentation therapy in vitiligo universalis with topical 4-methoxyphenol and the Qswitched ruby laser. J Am Acad Dermatol. 2000; 42:760-9.
13. Nelson JS, Applebaum J. Treatment of superficial cutaneous pigmented lesions by melanin-specific selective photothermolysis using the Q-switched ruby laser. Ann Plast Surg. 1992;29:231–7.
14. van Geel N, Speeckaert R, De Wolf J, et al. Clinical significance of Koebner phenomenon in vitiligo. Br J Dermatol. 2012;167:1017–24.
15. Kim YJ, Chung BS, Choi KC. Depigmentation therapy with Q-switched ruby laser after tanning in vitiligo universalis. Dermatol Surg. 2001;27:969- 70.
16. Boukari F, Lacour JP, Ortonne JP, Bahadoran P, Passeron T. Laser-assisted depigmentation for resistant vitiligo: a retrospective case series with long-term follow-up. J Eur Acad Dermatol Venereol. 2014; 28: 374-7.
17. Grimes PE, Nashawati R. Depigmentation therapies for vitiligo. Dermatol Clin. 2017; 35: 219-27.
18. Rodrigues M. Skin cancer risk (Nonmelanoma skin cancers/melanoma) in vitiligo patients. Dermatol Clin. 2017; 35: 129-34.
Downloads
Published
How to Cite
Issue
Section
License
เนื้อหาและข้อมูลในบทความที่ลงตีพิมพ์ในวารสารโรคผิวหนัง ถือเป็นข้อคิดเห็นและความรับผิดชอบของผู้เขียนบทความโดยตรงซึ่งกองบรรณาธิการวารสาร ไม่จำเป็นต้องเห็นด้วย หรือร่วมรับผิดชอบใดๆ
บทความ ข้อมูล เนื้อหา รูปภาพ ฯลฯ ที่ได้รับการตีพิมพ์ในวารสารโรคผิวหนัง ถือเป็นลิขสิทธิ์ของวารสารฯ หากบุคคลหรือหน่วยงานใดต้องการนำทั้งหมดหรือส่วนหนึ่งส่วนใดไปเผยแพร่ต่อหรือเพื่อกระทำการใดๆ จะต้องได้รับอนุญาตเป็นลายลักอักษรจากบรรณาธิการวารสารโรคผิวหนังก่อนเท่านั้น
